FindTrial
Sign In

Background treatment

DRUG5 trials

Sponsors

Regeneron Pharmaceuticals, GBG Forschungs GmbH, Galvani Bioelectronics, TenNor Therapeutics Inc.

Conditions

Atopic DermatitisAtopic Dermatitis (AD)Breast Cancer Female NOSHER-2 Positive Breast CancerInflammatory Breast CancerInflammatory Breast Cancer Stage IVInvasive Ductal Breast CancerMucinous Breast Cancer Stage II

Phase 1

Safety and Tolerability of Dupilumab in Participants With Moderate to Severe Atopic Dermatitis
CompletedNCT01385657
Regeneron PharmaceuticalsAtopic Dermatitis
Start: 2011-07-31End: 2012-03-31Updated: 2020-02-26
A Phase 1/2 Study to Evaluate the Safety, PK and Efficacy of TNP-2092 Administered Via IA Injection in PJI Participants
RecruitingNCT06889701
TenNor Therapeutics Inc.Periprosthetic Joint Infection (PJI)
Start: 2025-04-03End: 2026-08-01Target: 33Updated: 2026-03-05

Phase 2

Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer
CompletedNCT01426880
GBG Forschungs GmbHBreast Cancer Female NOS, HER-2 Positive Breast Cancer, Inflammatory Breast Cancer +5
Start: 2011-08-31End: 2013-08-31Updated: 2016-02-15
Study to Determine the Safety and Effectiveness of Dupilumab for Treatment of Atopic Dermatitis (AD)
CompletedNCT01979016
Regeneron PharmaceuticalsAtopic Dermatitis (AD)
Start: 2013-12-31End: 2015-01-31Updated: 2020-03-18

Unknown Phase

ConsideRAte Study - Splenic Stimulation for RA
RecruitingNCT05003310
Galvani BioelectronicsRheumatoid Arthritis
Start: 2021-10-19End: 2032-04-30Target: 28Updated: 2024-05-22

Related Papers

Abstract RF2-02: Pooled analysis of the BrighTNess, CALGB 40603 (Alliance), and GeparSixto clinical trials identifies the impact of neoadjuvant carboplatin on pCR and survival in early-stage triple-negative breast cancer
Clinical Cancer Research2026-02-17
Abstract P1-01-18: Prevalence of functional HRD by the RAD51 assay: a pooled analysis with 367 patients from BRCA-associated tumor types
Clinical Cancer Research2025-06-13
Transcutaneous vagus nerve stimulation has no anti-inflammatory effect in diabetes
Scientific Reports2024-09-096 citations
An Analysis of <i>PIK3CA</i> Hotspot Mutations and Response to Neoadjuvant Therapy in Patients with Breast Cancer from Four Prospective Clinical Trials
Clinical Cancer Research2024-06-055 citations
Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis
American Journal of Clinical Dermatology2020-06-17128 citations
PIK3CA H1047R Mutation Associated with a Lower Pathological Complete Response Rate in Triple-Negative Breast Cancer Patients Treated with Anthracycline-Taxane–Based Neoadjuvant Chemotherapy
Cancer Research and Treatment2020-02-0485 citations
Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis.
2018-09-05492 citations
Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer
JAMA Oncology2017-07-17385 citations
Abstract P1-09-02: Homologous repair deficiency (HRD) as measure to predict the effect of carboplatin on survival in the neoadjuvant phase II trial GeparSixto in triple-negative early breast cancer
Cancer Research2017-02-153 citations
Abstract S2-04: Early survival analysis of the randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (GeparSixto)
Cancer Research2016-02-1562 citations
Prediction of pathological complete response (pCR) by Homologous Recombination Deficiency (HRD) after carboplatin-containing neoadjuvant chemotherapy in patients with TNBC: Results from GeparSixto.
Journal of Clinical Oncology2015-05-2046 citations
Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis
New England Journal of Medicine2014-07-091382 citations
Pathological complete response (pCR) rates after carboplatin-containing neoadjuvant chemotherapy in patients with germline <i>BRCA</i> (g<i>BRCA</i>) mutation and triple-negative breast cancer (TNBC): Results from GeparSixto.
Journal of Clinical Oncology2014-05-2060 citations
Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial.
2014-04-30691 citations